18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an open-label PET/CT study to investigate the safety and clinical monitoring value of 18F-grazy-02 in patients with lymphoma or solid tumors receiving immunotherapy, including immune checkpoint inhibition and CAR-T cell therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 75 lat.
- •Stan ogólny dobry (niezależny lub częściowo zależny od pomocy innych).
- •Pacjenci z podejrzeniem lub potwierdzonym rakiem płuca (nie drobnokomórkowym) lub czerniakiem, u których lekarze zalecają badanie PET/CT w celu diagnozy lub określenia stopnia zaawansowania choroby.
✗ Disqualifies
- •Kobiety w ciąży lub karmiące piersią.
- •Ciężkie problemy z wątrobą lub nerkami.
- •Niski poziom białych krwinek (poniżej 3 miliardów na litr).
- •Brak możliwości wykonania badania PET/CT.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- July 31, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Peking University Cancer Hospital & Institute
Beijing, China
Trial contact
Linyu Zhang
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.